Lapatinib plus Letrozole as First-Line Therapy for HER-2+ Hormone Receptor-Positive Metastatic Breast Cancer (vol 15, pg 122, 2010)

被引：11
|
作者：
Schwartzberg, Lee S.
Franco, Sandra X.
Florance, Allison
O'Rourke, Lisa
Maltzman, Julie
Johnston, Stephen
机构：
来源：
ONCOLOGIST | 2010年 / 15卷 / 03期
关键词：
D O I：
10.1634/theoncologist.2009-0240erratum
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：327 / 327
页数：1
相关论文
共 50 条
  • [21] A cost-effectiveness analysis of palbociclib plus letrozole as first-line treatment for estrogen receptor-positive, HER2-negative, metastatic breast cancer.
    Matter-Walstra, Klazien
    Schwenkglenks, Matthias
    Brauchli, Peter
    Klingbiel, Dirk
    Dedes, Konstantin J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [22] First-line ribociclib plus endocrine therapy in hormone receptor-positive, HER2-negative advanced breast cancer: A pooled efficacy analysis
    Tripathy, D.
    Hortobagyi, G.
    Chan, A.
    Im, S-A
    Chia, S.
    Yardley, D.
    Esteva, F. J.
    Hurvitz, S.
    Kong, O.
    Bao, W.
    Lorenc, K. Rodriguez
    Diaz-Padilla, I.
    Slamon, D. J.
    CANCER RESEARCH, 2019, 79 (04)
  • [23] Definition of First-Line Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer
    Reinert, Tomas
    Barrios, Carlos H.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (16) : 1959 - +
  • [24] Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+advanced or metastatic breast cancer(MBC)
    Riemsma, Rob
    Forbes, Carol A.
    Amonkar, Mayur M.
    Lykopoulos, Konstantinos
    Diaz, Jose R.
    Kleijnen, Jos
    Rea, Daniel W.
    CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (08) : 1263 - 1279
  • [25] Lapatinib in Postmenopausal Women with Hormone Receptor-Positive, HER2-Positive Metastatic Breast Cancer Profile Report
    Curran, Monique P.
    BIODRUGS, 2011, 25 (01) : 53 - 54
  • [26] SYSTEMATIC REVIEW OF LAPATINIB PLUS LETROZOLE WITH OTHER FIRST LINE TREATMENTS FOR HORMONE POSITIVE (HR+) HER2+ADVANCED OR METASTATIC BREAST CANCER (MBC)
    Riemsma, R.
    Forbes, C. A.
    Amonkar, M.
    Lykopoulos, K.
    Diaz, J. R.
    Kleijnen, J.
    Rea, D. W.
    VALUE IN HEALTH, 2010, 13 (07) : A253 - A253
  • [27] Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer (vol 29, pg 1541, 2018)
    Hortobagyi, G. N.
    Stemmer, S. M.
    Burris, H. A.
    Yap, Y. S.
    Sonke, G. S.
    Paluch-Shimon, S.
    Campone, M.
    Petrakova, K.
    Blackwell, K. L.
    Winer, E. P.
    Janni, W.
    Verma, S.
    Conte, P.
    Arteaga, C. L.
    Cameron, D. A.
    Mondal, S.
    Su, F.
    Miller, M.
    Elmeliegy, M.
    Germa, C.
    O'Shaughnessy, J.
    ANNALS OF ONCOLOGY, 2019, 30 (11) : 1842 - 1842
  • [28] Phase I/II study of letrozole and sorafenib as first-line therapy of hormone-receptor positive (HR plus ) metastatic breast cancer (MBC).
    Tan, Antoinette R.
    Wong, Serena Tsan-Lai
    Warren, Robert D.
    Eng-Wong, Jennifer
    Liu, Minetta C.
    Zelnak, Amelia Bruce
    Lin, Yong
    Shih, Weichung
    Ganesan, Shridar
    Grana, Generosa
    Isaacs, Claudine
    Toppmeyer, Deborah
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [29] Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib
    Prat, Aleix
    Cheang, Maggie C. U.
    Galvan, Patricia
    Nuciforo, Paolo
    Pare, Laia
    Adamo, Barbara
    Munoz, Montserrat
    Viladot, Margarida
    Press, Michael F.
    Gagnon, Robert
    Ellis, Catherine
    Johnston, Stephen
    JAMA ONCOLOGY, 2016, 2 (10) : 1287 - 1294
  • [30] Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
    Alessandra Fabi
    Michelangelo Russillo
    Gianluigi Ferretti
    Giulio Metro
    Cecilia Nisticò
    Paola Papaldo
    Ferdinando De Vita
    Giuliana D’Auria
    Antonello Vidiri
    Diana Giannarelli
    Francesco Cognetti
    BMC Cancer, 12
12345